Orphan Therapeutics, LLC is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for its first product terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US, Canada and Japan. In March 2010, Orphan Therapeutics licensed the New Drug Application (NDA) and its development rights for terlipressin in North America and Australia to Ikaria Inc., which was acquired by Mallinckrodt in April 2015. Orphan Therapeutics has a continued commitment to assist the Mallinckrodt team through the FDA approval process.

In the News...

November 11, 2019

Mallinckrodt Presents Positive Results from its CONFIRM Study 

October 21, 2019

Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study 

August 15, 2019

Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial

December 7, 2015

Mallinckrodt plc Discusses R&D Initiatives, Company Outlook at Investor Briefing

read more....